Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression-Reference-Cited by-同舟云学术

Prostate-specific antigen decline pattern in advanced prostate cancer receiving androgen deprivation therapy and relationship with prostate-specific antigen progression

Published:2017-05-20 Issue: Volume: Page:1-9
ISSN:1368-5538
Container-title:The Aging Male
language:en
Short-container-title:The Aging Male

Author:

Akbay Erdem,Bozlu Murat,Çayan Selahittin,Kara Pelin Özcan,Tek Mesut,Aytekin Cuma

Publisher

Informa UK Limited

Subject

Geriatrics and Gerontology

Link

https://www.tandfonline.com/doi/pdf/10.1080/13685538.2017.1328675

Reference31 articles.

1. A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

2. A Urologist’s Personal View of Prostate Cancer

3. Absolute Prostate-Specific Antigen Value After Androgen Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162)

4. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy

5. Prognostic Significance of Time to Prostate-Specific Antigen (PSA) Nadir and Its Relationship to Survival Beyond Time to PSA Nadir for Prostate Cancer Patients With Bone Metastases After Primary Androgen Deprivation Therapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy;Journal of Cancer Research and Therapeutics;2023-12-15

2. The slope associated with nadir prostate‐specific antigen is prognostically significant in men with hormone‐sensitive prostate cancer after primary androgen deprivation therapy;Cancer Medicine;2022-03-21

3. Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy;Journal of Oncology;2021-08-26

4. PSA nadir and time to PSA nadir during initial androgen deprivation therapy as prognostic factors in metastatic castration‐resistance prostate cancer patients treated with docetaxel;Andrologia;2021-02-16

5. The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients;Journal of Clinical Medicine;2018-12-18